Purpose: The global incidence of oropharyngeal squamous cell carcinoma (OPSCC) has been increasing, and it has been proposed that a rising rate of human papillomavirus (HPV)-associated cancers is driving the observed changes in OPSCC incidence. We carried out this systematic review to further examine the prevalence of HPV in OPSCC over time worldwide.
H ead and neck squamous cell carcinoma represents the eighth most common cancer worldwide. 1 The oropharynx (tonsils, soft palate, base of tongue, and lateral/posterior pharyngeal walls) is an important region of the head and neck. Recently, numerous groups have revealed a rising incidence of oropharyngeal squamous cell carcinoma (OPSCC) in their respective country, particularly in white men. [2] [3] [4] [5] [6] [7] Chaturvedi et al 8 confirmed OPSCC incidence has increased globally, and they also showed there has been a decrease in the incidence of other oral cavity cancers among men, likely due to declines in alcohol and tobacco abuse. With the emergence of these data, there has been a drive to understand why the incidence of OPSCC is rising, while other cancers of the head and neck are decreasing.
Because human papillomavirus (HPV) is a causal factor in a subset of OPSCCs, 9 it has been proposed that a steadily rising rate of HPV-associated cancers has led to the changes in OPSCC incidence. Several groups have compared the percentage of HPV-positive OPSCCs within different time periods for patient populations in their country. Across the Netherlands, the prevalence of HPV in OPSCC rose from 5% to 29% between 1990 and 2010. 10 Hong et al 11 demonstrated an increase from 19% in 1987 to 1990 to 47% for 2001 to 2005 in Australia. In the United States, Chaturvedi et al 12 showed a significant increase from 16.3% for 1984 to 1989 to 72.7% by 2000 to 2004. Additional studies with patients from other countries also revealed a rise in the frequency of HPV-positive OPSCCs over time. [13] [14] [15] [16] [17] [18] Based on these data, it appears that a rising prevalence of HPV-positive OPSCCs could be driving the observed changes in the incidence of OPSCC. However, the vast majority of studies that have evaluated the HPV status of OPSCCs derive their samples from a relatively short period and a single region within 1 country.
We performed this systematic review to analyze changes in the worldwide prevalence of HPV in OPSCC. Several groups have recently published pooled analyses describing HPV in head and neck cancer. 19, 20 Ndiaye et al 19 described the global burden of HPV in multiple head and neck subsites (oropharynx, hypopharynx/ larynx, and oral cavity). They compared various HPV detection techniques and demonstrated a high correlation between p16 immunohistochemistry (IHC) and HPV DNA polymerase chain reaction (PCR)-based approaches for identifying HPV-positive oropharyngeal cancers. Significantly, this relationship did not exist among the nonoropharyngeal cancers. Mehanna and colleagues 20 described changes in the prevalence of HPV-positive OPSCCs through the year 2010. However, they included multiple studies with overlapping patients, so in an effort to avoid this bias, we systematically excluded articles analyzing the same patient population. Moreover, our study includes 38 articles published after 2010 describing almost 5000 patients who would not have been available to Mehanna et al. 20 Overall, in this work, we examine time trends in the worldwide prevalence of HPV-positive OPSCCs. By using a statistical model, we combined data from all available articles to determine whether the frequency of these cancers has truly increased over the past few decades. Human papillomavirus-positive OPSCC is a distinct disease entity with an improved prognosis, 21, 22 and the results of this study may have important implications regarding predictions for the future incidence of OPSCC and in the planning of future studies related to this disease.
METHODS
We followed the PRISMA guidelines throughout our analysis and manuscript preparation. 23 Detailed methods are provided in the online-only data supplement (http://links.lww.com/PPO/A15).
Article Selection
A systematic literature review was performed using the National Institutes of Health PubMed search engine to identify articles published through January 31, 2014, reporting on the prevalence of HPV in OPSCC by PCR, in situ hybridization (ISH), p16 IHC, or other molecular methods. Studies that met these initial criteria were selected for detailed evaluation of the entire study. Reviewing the reference sections of this initial cohort of articles identified additional relevant articles.
To be included in our analysis, all articles needed to present the first and last years that their samples derived from (sample collection period), number of HPV-positive OPSCCs, total number of OPSCCs analyzed, and the country/region where the samples originated. Eighteen articles did not report the sample collection period, and 3 failed to present the number of HPV-positive OPSCCs detected. Before excluding these articles, we contacted the authors to gather the missing information (16 authors provided us with the necessary data). Finally, we carefully examined all articles in order to exclude ones with overlapping patient populations (included article reporting on the larger number of patients) ( Supplemental Table S1 , http://links.lww.com/PPO/A15).
Data Abstraction and Organization
Data extracted from each article is documented in Supplemental Table S2 (http://links.lww.com/PPO/A15). We stratified the head and neck cancers reported by each study into oropharyngeal and nonoropharyngeal subgroups and recorded the number of HPV-positive OPSCCs out of the total number of OPSCCs evaluated. Studies were separated into distinct geographical regions: North America, Europe, and other (including Asia, Australia, South America, and international because of the small number of articles from these regions). To assess changes in the prevalence of HPV-positive OPSCCs over time, we used the median year of each article's sample collection period (rounded down to the nearest year) to separate articles into 4 discrete time frames: pre-1995, 1995 to 1999, 2000 to 2004 and 2005 to present. For example, an article with samples derived from the years 1998 to 2004 would have a median year of 2001, and thus the data from that article would be categorized into the 2000 to 2004 time frame. Finally, the cutoff years for the time frames were chosen because they provided the most even distribution of articles across the 4 time frames and thereby maximized the potential of our statistical analyses.
Statistical Analysis
Because of the small number of articles for individual countries, we could not examine trends over time for each nation (aside from the United States 24 ). Therefore, we examined broader regions and determined if HPV prevalence changed over time worldwide, in North America and throughout Europe. There were not sufficient articles from specific geographic regions such as Asia, Australia, or South America to perform informative analyses on these individual areas.
In addition, all articles within a particular region were combined together into a single analysis regardless of the detection method utilized (PCR, ISH, p16, etc). The number of articles using methods other than PCR was too small to perform relevant statistical analyses assessing trends over time for each distinct detection method.
Human papillomavirus prevalence was calculated for each article by dividing the number of patients with HPV-positive OPSCCs by the total number of OPSCCs analyzed. An analysis of variance model with time frame used as a 4-level categorical variable and weighted by the total number of OPSCCs analyzed in each article was utilized to model the time trends of HPV in OPSCC. Two-sided tests and P < 0.05 were used to determine statistical significance.
RESULTS

Article Selection and Characteristics
Based on our broad PubMed searches, 699 unique articles were identified. Following careful article evaluation and the described exclusion/inclusion process, 105 articles were included Prevalence of HPV in OPSCC in our analysis ( Fig. 1 ). These 105 articles evaluated 9541 OPSCC specimens for the presence of HPV. Each article presented data for a median of 65 patients (range, 5-711 patients). Seventy-two studies used PCR-based methods, 12 used ISH, 9 used p16 IHC with PCR, 6 used p16 IHC alone, and 6 used other methods (2 used p16 IHC + ISH + PCR, 2 used PCR with flight mass spectroscopy, 1 used ISH + PCR, and 1 used Southern blot). The majority of articles analyzed formalin-fixed, paraffin-embedded (FFPE) tumors (n = 72), followed by fresh frozen tissue (n = 20), a combination of both FFPE and fresh frozen (n = 12), and 1 article did not report the tissue type analyzed. Finally, studies derived from 23 different countries spanning 5 continents (Supplemental Table S3 , http://links.lww.com/PPO/A15).
HPV Prevalence in OPSCC by Region
To assess changes over time related to the prevalence of HPV in OPSCC, we evaluated 3 geographic regions: worldwide, North America, and Europe and separated articles into 4 time frames: pre-1995, 1995 to 1999, 2000 to 2004, and 2005 to present based on each study's median year of sample collection (Figs. 2 and 3). We demonstrated a significant increasing trend of HPV-positive OPSCCs over time worldwide (P < 0.001). The mean prevalence was 32.3% (95% confidence interval [CI], 23.7%-40.7%) for pre-1995, 37.0% (95% CI, 30.1%-44.0%) in 1995 to 1999, 51.8% (95% CI, 46.7%-56.9%) for 2000 to 2004, and 52.9% (95% CI, 42.8%-63.0%) by 2005 to present. Across North America, there was also a significant trend (95% CI, P = 0.013), and the mean prevalence was 43.1% (95% CI, 28.8%-57.4%) in pre-1995, 47.3% (95% CI, 31.3%-63.3%) from 1995 to 1999, 66.6% (95% CI, 59.0%-74.2%) by 2000 to 2004, and 64.7% (95% CI, 48.0%-81.4%) for 2005 to present. Finally, data from Europe revealed a significant trend (P = 0.033), with the prevalence rising from 28.0% (95% CI, 18.2%-37.7%) for pre-1995, to 35 .6% (95% CI, 26.5%-44.7%) in 1995 to 1999, 42.4% (95% CI, 35.6%-49.1%) within 2000 to 2004, and eventually to 49.5% (95% CI, 36.4%-62.6%) by 2005 to present.
The mean prevalence of HPV-positive OPSCCs in North America increased by 4.2% (95% CI, −17.3% to 25.7%) from pre-1995 to 1995 to 1999, rose by 19.3% (95% CI, 1.6%-37.0%) between the periods 1995 to 1999 and 2000 to 2004, and then decreased by 1.9% (95% CI, −16.5 to 20.3%) from 2000 to 2004 to 2005 to present. Across Europe, there appears to be a steady increase in mean prevalence of HPV-positive cancers: 7.6% (95% CI, −5.6% to 21.0%) from pre-1995 to 1995 to 1999, 6.8% (95% CI, −4.6% to 18.1%) from 1995 to 1999 to 2000 to 2004, and 7.1% (95% CI, −7.6% to 21.8%) from 2000 to 2004 to 2005 to present (Table 1) .
Next, we determined the present-day frequency of HPVpositive OPSCCs by country (2000 to present time frame; Fig. 4 ). Thirteen of 18 countries had values between 39.5% and 75.0%. Taiwan was at the high end with 75.0% (95% CI, 64.9%-83.4%), and Spain had the lowest value at 6.1% (95% CI, 2.0%-13.7%). At 6.1% and 21.9% (95% CI, 19.3%-24.6%), Spain and the Netherlands, respectively, had lower HPV-positive frequencies than Europe as a whole. Within North America the United States, Canada and Mexico all had prevalence values between 61.1% and 71.3%, whereas a study from Greenland reported 25.0% (95% CI, 7.3%-52.4%). Because of the limited number of articles available for this analysis from many of the countries, these results must be interpreted with caution.
HPV Subtypes
Fifty-eight articles presented HPV subtype information on a total of 2363 HPV-positive OPSCCs. Kreimer et al 25 previously revealed HPV16 was the most prevalent subtype in OPSCC followed by types 18, 33, and 35, so we focused on documenting the distribution of these 4 subtypes. Examining all 58 articles demonstrated an HPV16 prevalence of 93.1%, followed by HPV33 at 1.4%, HPV18 at 1.3%, and HPV35 at 0.5%, and all other genotypes had a combined prevalence of 4.2%. The same analysis was carried out for North America, Europe, and other. All 3 regions demonstrated a similar trend with at least 90.0% of HPV-positive cancers represented by HPV16 along with much lower prevalence values for subtypes 18, 33, and 35 ( Table 2 ).
Analysis of Potential Confounding Variables
We carried out a series of analyses to address potential confounding factors, including degradation of earlier collected tissue samples, changes in HPV detection method sensitivities over time, and differences in preservation and detection techniques. To assess sample degradation, we identified articles with a greater than 10-year gap between the publication year and the first year of sample collection. Sixty-five articles fell into this group. Forty-eight of the 65 articles carried out DNA integrity measures by amplifying β-globin, actin, GAPDH, or another housekeeping gene prior to performing HPV detection. To ensure the 17 articles that failed to carry out these measures did not influence our results, we excluded them and repeated the primary analysis for the FIGURE 3 . Frequency of HPV-positive OPSCCs worldwide, in North America, and across Europe. Shaded maps representing the prevalence of HPV-positive OPSCCs in each region within a specified time frame. As the map's color shifts from yellow to orange to red, the prevalence of HPV is increasing. Documented below each map is the number of articles analyzed, total number of OPSCCs evaluated, and the pooled mean HPV prevalence value and associated 95% confidence interval for that specific region and time frame. *P < 0.05, **P < 0.01.
The Cancer Journal • Volume 21, Number 3, May/June 2015 Prevalence of HPV in OPSCC worldwide articles. As shown in Table 3 , the means and overall trend appear unchanged from the initial analysis. Next, improvements in HPV detection sensitivity could lead to an artificial increase in prevalence over time. We examined articles with a median year of sample collection in the pre-1995 time frame and stratified them into 2 groups: those published before 2000 (potentially using older methods) and articles published 2000 to present (likely using newer detection techniques). We calculated and compared the mean HPV prevalence for these 2 groups (Table 3 ) and found no statistically significant difference between them (P = 0.701). Then, we evaluated if the type of detection method had any impact by comparing PCR and ISH. We selected articles with a sample collection median year in the 2000 to 2004 time frame as this era contained the greatest number of articles performing ISH. There was no difference in the mean HPV prevalence value determined by these 2 methods (P = 0.615; Table 3 ). We could not carry out statistical analyses comparing p16 to PCR or ISH because of the small number of articles performing p16 alone. Importantly, a recent analysis demonstrated that 86.7% of HPV DNA PCR-positive OPSCCs are also p16 positive. 19 Finally, we compared the HPV-positive prevalence for FFPE specimens versus fresh frozen tumors. We examined studies with median year of sample collection within the 1995to-1999 time frame because this era had the largest number of articles utilizing fresh frozen tissue. We did not find any difference when comparing the frequency of HPV-positive OPSCCs for FFPE samples to fresh frozen tissue (P = 0.319; Table 3 ).
DISCUSSION
In order to elucidate the current worldwide trends for HPV prevalence in OPSCC, we undertook this systematic review and used a statistical model to examine all published literature through January 31, 2014, that documented the percentage of HPVpositive OPSCCs from patient populations across the world. We found there to be a significant increase in the prevalence of HPV in OPSCC worldwide, in North America, and across Europe. This information provides further evidence that HPV likely contributed to the rising incidence of OPSCC observed in recent years. Interestingly, the prevalence of HPV-positive OPSCC in North America increased in the 1990s, rose dramatically at the turn of the 21st century, and has apparently plateaued during the last decade at about 65% (Fig. 2) . In contrast, Europe demonstrated a gradual increase in HPV prevalence that has continued to the present day. The fact that HPV prevalence may have plateaued in North America could impact future projections related to the overall incidence of OPSCC. Chaturvedi et al 12 used a statistical model to predict future incidence of OPSCC in the United States and determined that the number of cases of HPVpositive OPSCC would continue to increase and eventually surpass the number of cervical carcinoma cases by 2020. However, this prediction assumed that the current observed increases in incidence for OPSCC would continue into the future. But if HPV-associated cancers were driving the incidence of OPSCC and if they have now reached a plateau in North America, then we might expect to see a leveling off of total OPSCC incidence as well. The potential plateau we have observed in the prevalence of HPV in OPSCC across North America represents an interesting finding that has not been reported by other groups evaluating patient populations within North America. Importantly, a recent analysis by Nasman et al 26 revealed a leveling off of the incidence of HPV-positive tonsillar squamous cell carcinoma in Sweden since 2008.
An understanding of the epidemiology of both HPV-negative and HPV-positive OPSCC is required to explore the possible reasons behind our results. Patients with HPV-negative OPSCC are generally older and have a history of substantial alcohol and tobacco abuse. Conversely, patients with HPV-positive cancers tend to be younger and have distinct risk factors including a high number of sexual partners, early age at first sexual encounter, and prior history of sexually transmitted infections. 27, 28 Owing to these unique risk factor profiles, it has been suggested that changing sexual practices, in particular increasing oral sexual behavior, *For this analysis, 17 articles were excluded that did not carry out DNA integrity measures and had greater than a 10-year gap between publication year and first year of sample collection. Then, we repeated the same statistical analysis that was previously carried out for the worldwide articles (Fig. 3) . The P value for this analysis represents the trend in the percentage of HPV-positive OPSCCs over the 4 time frames.
†P < 0.01. ‡Median year: median year of each study's sample collection period.
The Cancer Journal • Volume 21, Number 3, May/June 2015 Prevalence of HPV in OPSCC may have led to higher rates of oral HPV infection and ultimately HPV-positive OPSCCs. The United States is the only country with significant studies reporting time-based trends of oral sexual behavior, and studies spanning from the 1940s to the present day appear to support the notion of increasing oral sexual behavior. The number of men who ever engaged in oral sex rose from 10% in the 1940s/1950s to approximately 50% by the 1970s/ 1980s 29 and continued to rise to 75% by 1991 30 and 85% by 2010. 31 Moreover, men exhibit greater rates of oral HPV infection as compared with women, 32 suggesting there may be sex-specific factors promoting this interaction or more efficient viral transmission from women to men. 31 These changing sexual practices could help explain the observed trends in the prevalence of HPV-positive OPSCCs in North America and Europe. Specifically, as there is likely a 20-to 30-year time lag between initial infection, tumorigenic progression, and emergence of cancer, the steep rise in HPV-positive OPSCCs seen at the turn of the 21st century in North America could reflect a more dramatic increase in oral sexual behavior in the 1970s/1980s. In comparison, these practices may be changing more gradually across many nations in Europe, leading to the more steady increase in HPV-positive OPSCCs. With respect to the plateau observed in North America, this could be a reflection of oral sexual behavior achieving a new norm in this region of the world. In addition, studies from Canada and the United States have revealed a decrease in smoking in both men and women since the 1950s/1960s. 33, 34 At least in the United States, the decline in smoking has started to slow down in recent years. 33 In this manner, it is possible that the major changes in sexual behavior and smoking habits occurred about 20 to 30 years ago across North America, and as a result, HPV-negative (primarily smoking related) and HPV-positive OPSCCs have now reached a new balance in the population.
Although we observed a plateau in HPV-positive OPSCCs in North America, we still anticipate prevalence values to remain high in this part of the world for a minimum of 20 to 30 years because oral sexual behavior remains common, 28 vaccination rates against HPV remain low in women and more so in men, 35 and people developing oral HPV infections today likely will not present with OPSCC until the year 2030 or 2040. As countries in Europe such as the Netherlands and Spain see higher levels of HPV-positive OPSCCs, 10, 17 we anticipate this cancer will continue to increase steadily in Europe. In this manner, HPV-positive OPSCC will remain a significant health burden worldwide for at least the next few decades. Therefore, this cancer represents an important disease for clinicians, scientists, epidemiologists, and public health advocates to be aware of and understand.
One potential way to reduce the future burden of HPVpositive OPSCCs would be to prevent the initial infection in young men and women by vaccinating against HPV. Currently, Gardasil (targets HPV types 6, 11, 16, and 18) and Cervarix (targets HPV types 16 and 18) represent the 2 available vaccines. Both have lowered the rates of cervical intraepithelial neoplasia in large randomized trials. 36, 37 Unfortunately, minimal information exists regarding the efficacy of these vaccines against OPSCC. However, a recent trial revealed a significant decrease in oral HPV infection in women receiving the vaccine versus control. 38 This trial, coupled with the fact that greater than 90% of HPV-positive OPSCCs are due to HPV16 and HPV18, suggests both vaccines could effectively prevent OPSCC.
As of 2012, both vaccines were licensed in more than 100 countries, and HPV vaccination had been incorporated into the national immunization programs of more than 40 countries. 39 In the majority of these countries, vaccine recommendations apply solely to females. Based on our detailed literature review, it appears that Australia, 40 Canada, 41 and the United States 42 are the only countries with recommendations for vaccinating males. Only the United States has documented the vaccine coverage for young men, and in 2010, 1.4% of males aged 13 to 17 received at least 1 dose of the vaccine. 43 Although this rose to 20.8% by 2012, only 6.8% of these males completed the recommended 3 dose vaccine series. 35 The high worldwide prevalence of HPVpositive OPSCC combined with likely protection conferred by vaccination against this and other HPV-related diseases should encourage all countries to implement and promote vaccination programs for both men and women.
We acknowledge several important limitations to this work. It is possible we have introduced publication bias because we focused solely on published literature. Moreover, our data were collected from a heterogeneous population of studies derived from different countries. There existed variability in the anatomic regions the authors evaluated as OPSCCs in their respective studies, which could have led to differences in the HPV prevalence values reported as a result of the original study design. Because patients with HPV-positive OPSCCs carry unique clinical and demographic characteristics, it is possible that our data are impacted by the fact that most of the studies we evaluated were drawn from academic medical centers, which could lead to an enriched dataset. As can be appreciated from Supplemental Table S3 (http://links.lww.com/PPO/A15), the number of articles and patients varied across countries. This resulted in the majority of articles deriving from North America (specifically the United States and Canada) and Europe (mainly Western Europe), with much lower representation from countries in Asia, Australia, South America, and Central America and no information from Africa. Based on this fact, it is important to understand that the data for the worldwide articles are driven primarily by the North America and Europe data. Certainly, it would be important moving forward for research groups in other regions of the world to evaluate the proportion of HPV-positive OPSCCs in their respective country to obtain a more accurate depiction of the prevalence of this cancer worldwide. The majority of articles retrospectively analyzed their OPSCC specimens from a multiyear period without providing year-by-year results, so we utilized the median year of each article's sample collection period in order to separate the data from each article into distinct time frames. It is possible this methodology could have impacted our results depending on the number of OPSCCs that each article analyzed from earlier versus later years as well as the range of years from which the samples were derived. Lastly, each article used different criteria for patient inclusion/exclusion and utilized different detection methods for defining HPV positivity.
Indeed, the wide array of available HPV detection methods warrants discussion of the advantages and disadvantages of certain approaches. In this systematic review, the majority of studies used HPV DNA PCR-based methods. Multiple primer sets exist for PCR such as L1 consensus primers that detect numerous HPV types, type-specific primers for high-risk HPVs, and commercial kits targeting a wide range of HPV sequences. In general, PCR is highly sensitive for detecting HPV DNA, but it cannot determine if the HPV originated in tumor cells versus adjacent nontumor tissue. In situ hybridization represents the second most frequently used method in our cohort of articles. Multiple probes are available for ISH including the Ventana INFORM HPV ISH assay (detects 12 high-risk HPVs) and HPV16-specific probes. In contrast to PCR, ISH reveals the cellular localization of the HPV. An important shortcoming of PCR and ISH-based techniques is that they solely demonstrate the presence of HPV without determining viral activity. One clinically validated method that identifies OPSCCs with transcriptionally active HPV is p16 IHC. [44] [45] [46] p16 is inhibited in vivo by the tumor suppressor retinoblastoma (Rb). Classically, the described mechanism of p16 overexpression in HPV-positive cancers has been attributed to 1 of HPV's oncogenes, E7, degrading Rb and thereby releasing p16 from its negative regulator. 47 However, McLaughlin-Drubin et al 48 have also shown that p16 overexpression arises independently from Rb degradation in HPV-positive cervical carcinoma cell lines. Recently, a 2-step approach combining a highly sensitive test (p16 IHC) with a specific one (HPV DNA ISH) has demonstrated efficacy in identifying HPV-positive tumors. 49, 50 Other molecular methods for identifying HPV-positive cancers include ones directly identifying HPV oncogenes E6 and E7, such as the newly validated E6/E7 RNA ISH assay. 51, 52 Indeed, the diversity among methods for determining HPV positivity demonstrates the need for a consensus committee to review the current techniques and develop recommendations for clinicians and scientists regarding best practices for identifying HPV-positive cancers. We believe moving forward that validated algorithms should demonstrate both the transcriptional activity and presence of HPV within tumor cells.
Considering the diversity of available detection methods, it would have been interesting to evaluate and compare HPV positivity in OPSCC over time by detection method. Unfortunately, the number of articles utilizing methods other than PCR was too small to stratify our data by detection method. Moreover, numerous different primer pairs were used for PCR testing by these studies, further limiting the ability to perform detection-specific analyses. In this manner, the most significant limitation of our study is that the results from all detection methods different articles were combined into a single analysis, and the majority of studies used PCR-based methods, which as described previously demonstrates only HPV presence and not activity. Importantly, Ndiaye et al 19 revealed that approximately 87% of HPV DNA PCR-positive OPSCCs were also positive for either p16 or E6/ E7 mRNA. Owing to the high level of correlation between these different tests in OPSCCs, our results should still maintain the temporal relationships demonstrated even if the articles had used p16 or E6/E7 mRNA in combination with (or in place of ) PCR.
In this study, we report the results of a comprehensive systematic review analyzing all published literature through January 2014 reporting on the prevalence of HPV in OPSCC. As expected, we demonstrated a significant increase in the prevalence of HPVpositive OPSCCs over time worldwide, which is consistent with HPV playing an important role in the observed increases in OPSCC incidence in recent years. Surprisingly, we also showed that HPV-positive OPSCCs have reached an apparent plateau in North America over the past decade, whereas the prevalence in Europe continues to rise steadily. Certainly, further data are needed to determine if these trends truly manifest themselves moving forward, but this information could have important implications regarding future predictions related to the incidence of OPSCC.
